Substituted 1,1,1-trifluoro-3-[(benzyl)-(pyrimidin-2-yl )-amino]-prop an-2-ol compounds

Details for Australian Patent Application No. 2006217630 (hide)

Owner Pfizer Products Inc.

Inventors Pence, Michael Patrick; Chang, George

Agent Allens Arthur Robinson

Pub. Number AU-A-2006217630

PCT Pub. Number WO2006/090250

Priority 60/655,740 23.02.05 US

Filing date 13 February 2006

Wipo publication date 31 August 2006

International Classifications

C07D 239/46 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

A61K 31/505 (2006.01) - Pyrimidines

A61P 3/06 (2006.01) Drugs for disorders of the metabolism

Event Publications

16 August 2007 PCT application entered the National Phase

  PCT publication WO2006/090250 Priority application(s): WO2006/090250

25 February 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006217642-Method of genotyping and phenotyping hepatitis B viruses resistant to antiviral molecules

2006217616-Preparation of high purity substituted quinoxaline